Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P33992
UPID:
MCM5_HUMAN
Alternative names:
CDC46 homolog; P1-CDC46
Alternative UPACC:
P33992; O60785; Q14578; Q9BTJ4; Q9BWL8
Background:
DNA replication licensing factor MCM5, also known as CDC46 homolog, is a pivotal component of the MCM2-7 complex, essential for initiating and elongating DNA replication in eukaryotic cells. It forms a core part of the CDC45-MCM-GINS helicase, unwinding DNA during replication. The protein's ATPase activity, critical for its function, arises from the interaction of neighboring subunits within the complex.
Therapeutic significance:
Understanding the role of DNA replication licensing factor MCM5 could open doors to potential therapeutic strategies, especially considering its involvement in Meier-Gorlin syndrome 8, a condition marked by growth retardation and skeletal anomalies. Targeting the protein's function might offer avenues for treating this genetic disorder.